Literature DB >> 34181630

An EUA for sotrovimab for treatment of COVID-19.

.   

Abstract

Entities:  

Keywords:  COVID-19; adverse effects; bamlanivimab; casirivimab; dosage; efficacy; etesevimab; imdevimab; safety; sotrovimab

Year:  2021        PMID： 34181630

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN： 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  14 in total

1.  Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.

Authors:  Ramesh K Paidi; Malabendu Jana; Rama K Mishra; Debashis Dutta; Kalipada Pahan
Journal:  J Immunol       Date:  2021-10-13       Impact factor: 5.422

Review 2.  Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.

Authors:  Daniel Clark Files; Frank Tacke; Alexandra O'Sullivan; Patrick Dorr; William G Ferguson; William G Powderly
Journal:  PLoS Pathog       Date:  2022-06-24       Impact factor: 7.464

Review 3.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

Review 4.  Antibodies to combat viral infections: development strategies and progress.

Authors:  Giuseppe Pantaleo; Bruno Correia; Craig Fenwick; Victor S Joo; Laurent Perez
Journal:  Nat Rev Drug Discov       Date:  2022-06-20       Impact factor: 112.288

5.  Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease.

Authors:  Kai S Yang; Syuan-Ting Alex Kuo; Lauren R Blankenship; Zhi Zachary Geng; Shuhua G Li; David H Russell; Xin Yan; Shiqing Xu; Wenshe Ray Liu
Journal:  Curr Res Chem Biol       Date:  2022-04-22

6.  VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes.

Authors:  Qinglan Sun; Chang Shu; Wenyu Shi; Yingfeng Luo; Guomei Fan; Jingyi Nie; Yuhai Bi; Qihui Wang; Jianxun Qi; Jian Lu; Yuanchun Zhou; Zhihong Shen; Zhen Meng; Xinjiao Zhang; Zhengfei Yu; Shenghan Gao; Linhuan Wu; Juncai Ma; Songnian Hu
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

7.  Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.

Authors:  Meiyu Wang; Li Zhang; Qianqian Li; Bo Wang; Ziteng Liang; Yeqing Sun; Jianhui Nie; Jiajing Wu; Xiaodong Su; Xiaowang Qu; Yuhua Li; Youchun Wang; Weijin Huang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

Review 8.  The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.

Authors:  Sylvia Annabel Dass; Venugopal Balakrishnan; Norsyahida Arifin; Crystale Siew Ying Lim; Fazlina Nordin; Gee Jun Tye
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

9.  Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.

Authors:  Susin Park; Nam Kyung Je; Dong Wan Kim; Miran Park; Jeonghun Heo
Journal:  J Korean Med Sci       Date:  2022-04-04       Impact factor: 2.153

Review 10.  Can anti-parasitic drugs help control COVID-19?

Authors:  Yasin Panahi; Masoomeh Dadkhah; Sahand Talei; Zahra Gharari; Vahid Asghariazar; Arash Abdolmaleki; Somayeh Matin; Soheila Molaei
Journal:  Future Virol       Date:  2022-03-18       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.